A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer ; volume:134 ; number:1 ; day:24 ; month:12 ; year:2011 ; pages:13-20 ; date:7.2012
Breast cancer research and treatment ; 134, Heft 1 (24.12.2011), 13-20, 7.2012
- Urheber
-
Rugo, Hope S.
Jo Chien, A.
Franco, Sandra X.
Stopeck, Alison T.
Glencer, Alexa
Lahiri, Soumi
Arbushites, Michael C.
Scott, Janet
Park, John W.
Hudis, Clifford
Nulsen, Ben
Dickler, Maura N.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-011-1918-z
- URN
-
urn:nbn:de:101:1-2019073121215923762244
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rugo, Hope S.
- Jo Chien, A.
- Franco, Sandra X.
- Stopeck, Alison T.
- Glencer, Alexa
- Lahiri, Soumi
- Arbushites, Michael C.
- Scott, Janet
- Park, John W.
- Hudis, Clifford
- Nulsen, Ben
- Dickler, Maura N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines